By Lynx Insight Service
Nov 5 (Reuters) - * Eagle Pharmaceuticals Inc EGRX.OQ
EGRX.O is expected to show a fall in quarterly revenue when it
reports results on November 9.
* The Woodcliff Lake, New Jersey-based company is expected to
report a 7.1% decrease in revenue to $46.4 million from $49.93
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Eagle Pharmaceuticals
Inc is for earnings of 83 cents per share. For the same quarter
last year, the company reported earnings of $1.17 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $48.5, about 7.1% below its last
closing price of $51.94.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 0.75 0.80 0.93 Beat 16.3
Mar. 31 2021 0.74 0.65 0.24 Missed -63.1
Dec. 31 2020 -0.20 -0.17 0.96 Beat 656.5
Sep. 30 2020 0.33 0.30 1.17 Beat 296.6
Jun. 0.26 0.24 0.57 Beat 142.6
30 2020
Mar. 31 2020 0.58 0.57 0.84 Beat 48
Dec. 31 2019 0.50 0.47 0.48 Beat 3.2
Sep. 30 2019 0.42 0.43 0.26 Missed -39.2
This summary was machine generated November 5 at 16:06 GMT. All
figures in US dollars unless otherwise stated.
()
((Reuters Messaging:))